Sulfaphenazole

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

磺胺苯唑是 CYP2C9 的抑制剂（Ki：0.3 μM），其选择性比其他 CYP450 亚型至少高 100 倍（Ki：对于 CYP2C8/CYP2C18 分别为 63/29 μM，对 CYP1A1、CYP1A2、CYP3A4、CYP2C19 无活性） 。

Sulfaphenazole is an inhibitor of CYP2C9 (Ki: 0.3 μM) that demonstrates at least 100-fold selectivity over other CYP450 isoforms (Ki: 63/29 μM for CYP2C8/CYP2C18, respectively, and no activity at CYP1A1, CYP1A2, CYP3A4, CYP2C19). At 10 μM, sulfaphenazole has been shown to inhibit endothelium-derived hyperpolarizing factor synthase, a CYP450 isozyme in the porcine coronary artery homologous to CYP2C8/9 that generates reactive oxygen species in coronary endothelial cells and modulates vascular tone and homeostasis.

Apoptosis Analysis Cell Line:661W cells Concentration:10 μM Incubation Time:For 1 h at 37 °C followed by light exposure for 2-3 h Result:The numbers of light-induced apoptotic and necrotic cells were decreased by 33 and 44%, respectively.

Animal Model:Diabetic male mice (db/db strain) Dosage:5.13 mg/kg Administration:Intraperitoneal injections; daily; for 8 weeks Result:Although sulfaphenazole did not change endothelium-dependent vasodilation in control mice, it restored endothelium-mediated relaxation in db/db mice.

BRN-0308518 | Sulfaphenazole | Firmazolo | Inamil

PI3K/Akt/mTOR signaling

GSK-3

CYP2C9

Infection

——

526-08-9

314.36

C15H14N4O2S

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 318.11 mM

Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1

4-amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide

(-20℃)

With Ice Pack

≥ 2 years